256 related articles for article (PubMed ID: 33935757)
21. In vivo inhibition of RIPK2 kinase alleviates inflammatory disease.
Tigno-Aranjuez JT; Benderitter P; Rombouts F; Deroose F; Bai X; Mattioli B; Cominelli F; Pizarro TT; Hoflack J; Abbott DW
J Biol Chem; 2014 Oct; 289(43):29651-64. PubMed ID: 25213858
[TBL] [Abstract][Full Text] [Related]
22. RICK/RIP2 is a NOD2-independent nodal point of gut inflammation.
Watanabe T; Minaga K; Kamata K; Sakurai T; Komeda Y; Nagai T; Kitani A; Tajima M; Fuss IJ; Kudo M; Strober W
Int Immunol; 2019 Sep; 31(10):669-683. PubMed ID: 31132297
[TBL] [Abstract][Full Text] [Related]
23. Nucleotide-binding oligomerization domain containing 2: structure, function, and diseases.
Yao Q
Semin Arthritis Rheum; 2013 Aug; 43(1):125-30. PubMed ID: 23352252
[TBL] [Abstract][Full Text] [Related]
24. XIAP controls RIPK2 signaling by preventing its deposition in speck-like structures.
Ellwanger K; Briese S; Arnold C; Kienes I; Heim V; Nachbur U; Kufer TA
Life Sci Alliance; 2019 Aug; 2(4):. PubMed ID: 31350258
[TBL] [Abstract][Full Text] [Related]
25. Discovery of Potent and Selective Receptor-Interacting Serine/Threonine Protein Kinase 2 (RIPK2) Inhibitors for the Treatment of Inflammatory Bowel Diseases (IBDs).
Yuan X; Chen Y; Tang M; Wei Y; Shi M; Yang Y; Zhou Y; Yang T; Liu J; Liu K; Deng D; Zhang C; Chen L
J Med Chem; 2022 Jul; 65(13):9312-9327. PubMed ID: 35709396
[TBL] [Abstract][Full Text] [Related]
26. Identification of Potent and Selective RIPK2 Inhibitors for the Treatment of Inflammatory Diseases.
He X; Da Ros S; Nelson J; Zhu X; Jiang T; Okram B; Jiang S; Michellys PY; Iskandar M; Espinola S; Jia Y; Bursulaya B; Kreusch A; Gao MY; Spraggon G; Baaten J; Clemmer L; Meeusen S; Huang D; Hill R; Nguyen-Tran V; Fathman J; Liu B; Tuntland T; Gordon P; Hollenbeck T; Ng K; Shi J; Bordone L; Liu H
ACS Med Chem Lett; 2017 Oct; 8(10):1048-1053. PubMed ID: 29057049
[TBL] [Abstract][Full Text] [Related]
27. Essential Role of the Innate Immune Adaptor RIP2 in the Response to Otitis Media.
Kurabi A; Lee J; Pak K; Leichtle A; Ryan AF
Front Genet; 2022; 13():893085. PubMed ID: 35903351
[TBL] [Abstract][Full Text] [Related]
28. A regulatory region on RIPK2 is required for XIAP binding and NOD signaling activity.
Heim VJ; Dagley LF; Stafford CA; Hansen FM; Clayer E; Bankovacki A; Webb AI; Lucet IS; Silke J; Nachbur U
EMBO Rep; 2020 Nov; 21(11):e50400. PubMed ID: 32954645
[TBL] [Abstract][Full Text] [Related]
29. The role of nucleotide-binding oligomerization domain 1 during cytokine production by macrophages in response to Mycobacterium tuberculosis infection.
Lee JY; Hwang EH; Kim DJ; Oh SM; Lee KB; Shin SJ; Park JH
Immunobiology; 2016 Jan; 221(1):70-5. PubMed ID: 26255090
[TBL] [Abstract][Full Text] [Related]
30. A RIPK2 inhibitor delays NOD signalling events yet prevents inflammatory cytokine production.
Nachbur U; Stafford CA; Bankovacki A; Zhan Y; Lindqvist LM; Fiil BK; Khakham Y; Ko HJ; Sandow JJ; Falk H; Holien JK; Chau D; Hildebrand J; Vince JE; Sharp PP; Webb AI; Jackman KA; Mühlen S; Kennedy CL; Lowes KN; Murphy JM; Gyrd-Hansen M; Parker MW; Hartland EL; Lew AM; Huang DC; Lessene G; Silke J
Nat Commun; 2015 Mar; 6():6442. PubMed ID: 25778803
[TBL] [Abstract][Full Text] [Related]
31. RIPK2 inhibitors for disease therapy: Current status and perspectives.
Tian E; Zhou C; Quan S; Su C; Zhang G; Yu Q; Li J; Zhang J
Eur J Med Chem; 2023 Nov; 259():115683. PubMed ID: 37531744
[TBL] [Abstract][Full Text] [Related]
32. Asparagine attenuates hepatic injury caused by lipopolysaccharide in weaned piglets associated with modulation of Toll-like receptor 4 and nucleotide-binding oligomerisation domain protein signalling and their negative regulators.
Wu H; Liu Y; Pi D; Leng W; Zhu H; Hou Y; Li S; Shi H; Wang X
Br J Nutr; 2015 Jul; 114(2):189-201. PubMed ID: 26079268
[TBL] [Abstract][Full Text] [Related]
33. Design, synthesis and evaluation of novel thieno[2,3d]pyrimidine derivatives as potent and specific RIPK2 inhibitors.
Misehe M; Šála M; Matoušová M; Hercík K; Kocek H; Chalupská D; Chaloupecká E; Hájek M; Boura E; Mertlíková-Kaiserová H; Nencka R
Bioorg Med Chem Lett; 2024 Jan; 97():129567. PubMed ID: 38008339
[TBL] [Abstract][Full Text] [Related]
34. Structural and functional insights into CARDs of zebrafish (Danio rerio) NOD1 and NOD2, and their interaction with adaptor protein RIP2.
Maharana J; Dehury B; Sahoo JR; Jena I; Bej A; Panda D; Sahoo BR; Patra MC; Pradhan SK
Mol Biosyst; 2015 Aug; 11(8):2324-36. PubMed ID: 26079944
[TBL] [Abstract][Full Text] [Related]
35. TRIP6 is a RIP2-associated common signaling component of multiple NF-kappaB activation pathways.
Li L; Bin LH; Li F; Liu Y; Chen D; Zhai Z; Shu HB
J Cell Sci; 2005 Feb; 118(Pt 3):555-63. PubMed ID: 15657077
[TBL] [Abstract][Full Text] [Related]
36. The crosstalk between TLR2 and NOD2 in Aspergillus fumigatus keratitis.
Wu J; Zhang Y; Xin Z; Wu X
Mol Immunol; 2015 Apr; 64(2):235-43. PubMed ID: 25549945
[TBL] [Abstract][Full Text] [Related]
37. Inductive expression of the NOD1 signalling pathway in chickens infected with Salmonella pullorum.
Tao Z; Zhu C; Song W; Xu W; Zhang S; Liu H; Li H
Br Poult Sci; 2017 Jun; 58(3):242-250. PubMed ID: 28084794
[TBL] [Abstract][Full Text] [Related]
38. Receptor-Interacting Protein Kinase-2 Inhibition by CYLD Impairs Antibacterial Immune Responses in Macrophages.
Wex K; Schmid U; Just S; Wang X; Wurm R; Naumann M; Schlüter D; Nishanth G
Front Immunol; 2015; 6():650. PubMed ID: 26834734
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis, and structure-activity relationship of novel RIPK2 inhibitors.
Wu S; Xu L; Wang X; Yang Q; Wang J; He S; Zhang X
Bioorg Med Chem Lett; 2022 Nov; 75():128968. PubMed ID: 36058467
[TBL] [Abstract][Full Text] [Related]
40. Role of nucleotide-binding oligomerization domain 1 (NOD1) in pericyte-mediated vascular inflammation.
Navarro R; Delgado-Wicke P; Nuñez-Prado N; Compte M; Blanco-Toribio A; Nuñez G; Álvarez-Vallina L; Sanz L
J Cell Mol Med; 2016 May; 20(5):980-6. PubMed ID: 26915562
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
